12/6/2019 9:16:44 AM
Aptevo Therapeutics Secures Orphan Drug Designation From FDA For APVO436 For Acute Myelogenous Leukemia
12/13/2018 9:02:44 AM
Aptevo Doses First Patient In Phase 1/1b Trial Of Lead Next-Generation Bispecific Antibody APVO436
11/9/2018 12:02:56 AM
Alligator Bioscience And Aptevo Therapeutics Present New Preclinical Data For ALG.APV-527 At SITC Annual Meeting
5/10/2018 9:02:55 AM
Aptevo Therapeutics Posts Q1 Net Loss Of $13.9 Mln Or $0.63/share
5/1/2018 9:04:43 AM
Aptevo Therapeutics Announces IND Submission For APVO436
3/13/2018 9:06:21 AM
Aptevo Therapeutics 2017 Net Income $7.0 Mln Or $0.33/shr Vs. Loss Of $112.4 Mln Or $5.55/shr Prior Year
1/8/2018 9:07:10 AM
Aptevo Therapeutics Begins Patient Dosing In Phase 2 Clinical Evaluation Of Otlertuzumab In New Indication